Bionano Genomics (BNGO) Cash from Operations (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Cash from Operations data on file, last reported at 5700000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 106.22% year-over-year to 5700000.0; the trailing twelve-month figure through Mar 2026 stood at 19236000.0 (up 55.84% YoY), and the FY2025 full-year result was 16300000.0, up 76.35% from the prior year.
• Cash from Operations eased to 5700000.0 in Q1 2026, from 4130000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 2764000.0 in Q1 2025 to a low of 36696000.0 in Q2 2023.
• A 5-year average of 20054058.82 and a median of 26293000.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 133.7% in 2022 and jumped 90.17% in 2025, its largest moves.
• Tracing BNGO's Cash from Operations over 5 years: stood at 34517000.0 in 2022, then rose by 13.73% to 29779000.0 in 2023, then surged by 78.16% to 6504000.0 in 2024, then surged by 36.5% to 4130000.0 in 2025, then sank by 38.01% to 5700000.0 in 2026.
• Business Quant data shows BNGO's Cash from Operations at 5700000.0 in Q1 2026, 4130000.0 in Q4 2025, and 5919000.0 in Q3 2025.